This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Cephalon, Inc.. Active years: 2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2015
Title: Pawel T Dobrzanski: Innovator in Chronic Inflammation Treatment
Introduction
Pawel T Dobrzanski is a notable inventor based in Downingtown, PA (US). He has made significant contributions to the field of medicine, particularly in the treatment of chronic inflammation and autoimmune diseases. With a total of 2 patents, his work has the potential to impact many lives.
Latest Patents
Dobrzanski's latest patents include innovative methods for treating chronic inflammation. One of his notable inventions is a treatment for chronic inflammation using a 1,2,4-triazolo [1,5a] pyridine derivative. This application describes a method for treating diseases characterized by chronic systemic inflammation, such as rheumatoid arthritis, through a compound that inhibits JAK2 kinase. Another significant patent focuses on a Janus kinase 2 (JAK2) inhibitor for the treatment of lupus. This invention provides a method for treating lupus in a subject by administering a specific compound.
Career Highlights
Pawel T Dobrzanski is currently associated with Cephalon, Inc., where he continues to develop innovative solutions in the medical field. His work is characterized by a commitment to addressing complex health issues through scientific research and development.
Collaborations
Throughout his career, Dobrzanski has collaborated with talented individuals, including Matthew Seavey and Matthew M Seavey. These collaborations have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Pawel T Dobrzanski is a dedicated inventor whose work in treating chronic inflammation and autoimmune diseases showcases his innovative spirit. His contributions to the field are significant and hold promise for future medical advancements.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile